Statistically Significant versus Practically Relevant Trend in Stability Data

References

1. 1.↵
   International Conference for Harmonisation, Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. ICH: Geneva, 2003.
2. 2.↵
   International Conference for Harmonisation, Harmonised Tripartite Guideline Q1C: Stability Testing for New Dosage Forms. ICH: Geneva, 1996.
3. 3.↵
   International Conference for Harmonisation, Harmonised Tripartite Guideline Q1E: Evaluation of Stability Data. ICH: Geneva, 2003.
4. 4.↵
   International Conference for Harmonisation, Harmonised Tripartite Guideline Q5C: Stability Testing of Biotechnological/Biological Products. ICH: Geneva, 1995.
5. 5.↵
   U.S. Food and Drug Administration, 21 CFR Part 211—Current Good Manufacturing Practice for Finished Pharmaceuticals, Subpart G—Packaging and Labeling Control, Section 211.137—Expiration Dating. U.S. Department of Health and Human Services. Government Publishing Office: Washington, DC, 2020.
6. 6.↵
   U.S. Food and Drug Administration, 21 CFR Part 211—Current Good Manufacturing Practice for Finished Pharmaceuticals, Subpart I—Laboratory Controls, Section 211.166—Stability Testing. U.S. Department of Health and Human Services. Government Publishing Office: Washington, DC, 2020.
7. 7.↵
   Committee for Proprietary Medicinal Products, CPMP/QWP/122/02 rev 1 Guideline on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products. EMA: London, 2004.
8. 8.↵
   Committee for Proprietary Medicinal Products, CPMP/QWP/576/96 Rev 1 Guideline on Stability Testing for Applications for Variations to a Marketing Authorization. EMA: London, 2005.
9. 9.↵
   National Health Surveillance Agency of Brazil. ANVISA Resolution RE No. 1—Guide for Undertaking Stability Studies. Ministry of Health, 2005.
10. 10.↵
    Association of South East Asian Nations. ASEAN Guideline on Stability Study of Drug Product. ASEAN: Jakarta, 2005.
11. 11.↵
    World Health Organization. WHO Technical report Series No. 953 Annex 2: Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. WHO: Geneva, 2009.
12. 12.↵
    1. Teasdale A.

    1. Elder D.

    1. Nims R. W.

    1. Davies J. G.,
    2. Gao D.,
    3. Kim Y. J.,
    4. Harris R.,
    5. Cash P. W.,
    6. Schofield T. L.,
    7. Zhang R.,
    8. Qin Q.

    ICH Q5C Stability Testing of Biotechnological/Biological Products. In: ICH Quality Guidelines: An Implementation Guide; Teasdale A.; Elder D.; Nims R. W., Eds.; Wiley Online Library: 2018; pp 345–374.
13. 13.↵
    1. Chow S.-C.

    Statistical Design and Analysis of Stability Studies, 1st ed.; Chapman & Hall/CRC: Boca Raton, FL, 2007.
14. 14.↵
    1. Burdick R. K.,
    2. Sidor L.

    Establishment of an Equivalence Acceptance Criterion for Accelerated Stability Studies. J. Biopharm. Stat. 2013, 23 (4), 730–743.

    OpenUrl
15. 15.↵
    1. Montes R. O.,
    2. Burdick R. K.,
    3. Leblond D. J.

    Simple Approach to Calculate Random Effects Model Tolerance Intervals to Set Release and Shelf-Life Specification Limits of Pharmaceutical Products. PDA J. Pharm. Sci. Technol. 2019, 73 (1), 39–59.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Wellek S.

    Testing Statistical Hypotheses of Equivalence and Noninferiority, 2nd ed.; Chapman & Hall/CRC: Boca Raton, FL, 2010.
17. 17.↵
    1. Schuirmann D. J.

    A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability. J. Pharmacokinet. Biopharm. 1987, 15 (6), 657–680.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Westlake W. J.

    Symmetrical Confidence Intervals for Bioequivalence Trials. Biometrics 1976, 32 (4), 741–744.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    U.S. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs—General Considerations. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2014.
20. 20.↵
    European Medicines Agency, Guideline on the Investigation of Bioequivalence. EMA: London, 2010.
21. 21.↵
    1. Owen D. B.

    A Special Case of a Bivariate Non-Central t-Distribution. Biometrika 1965, 52 (3–4), 437–446.

    OpenUrlCrossRef
22. 22.
    1. Tsong Y.,
    2. Dong X.,
    3. Shen M.

    Development of Statistical Methods for Analytical Similarity Assessment. J. Biopharm. Stat. 2017, 27 (2), 197–205.

    OpenUrl